2. Search Result
Search Result
Results for "

IL-6 and IL-8

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

2

Biochemical Assay Reagents

4

Peptides

5

Inhibitory Antibodies

12

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6927
    Isoforskolin

    Coleonol B

    		 TNF Receptor Interleukin Related Inflammation/Immunology
    Isoforskolin is the principle active component of C. forskohlii native to China. Isoforskolin reduces the secretion of lipopolysaccharide (LPS)-induced cytokines, namely TNF-α, IL-1β, IL-6 and IL-8, in human mononuclear leukocytes. Isoforskolin acts as an anti-inflammatory agent for the treatment of Lyme arthritis .
    Isoforskolin
  • HY-114592
    M199

    		Toll-like Receptor (TLR) Interleukin Related TNF Receptor Inflammation/Immunology
    M199 is a potent TLR3/TLR9 signaling inhibitor. M199 induces secretion of IL-6, IL-8 and TNFα in human PBMCs. M199 is used as a selective inducer of the immune response .
    M199
  • HY-N0314
    Pectolinarin
    2 Publications Verification

    		 Interleukin Related Prostaglandin Receptor Apoptosis Inflammation/Immunology
    Pectolinarin possesses anti-inflammatory activity . Pectolinarin inhibits secretion of IL-6 and IL-8, as well as the production of PGE2 and NO. Pectolinarin suppresses cell proliferation and inflammatory response and induces apoptosis via inactivation of the PI3K/Akt pathway .
    Pectolinarin
  • HY-N2572
    Nepetin

    6-Methoxyluteolin

    		 Interleukin Related Inflammation/Immunology
    Nepetin (6-Methoxyluteolin) is a natural flavonoid isolated from Eupatorium ballotaefolium HBK with potent anti-inflammatory activities. Nepetin inhibits IL-6, IL-8 and MCP-1 secretion with IC50 values of 4.43 μM, 3.42 μM and 4.17 μM, respectively in ARPE-19 cells .
    Nepetin
  • HY-147506
    NOD2 antagonist 1

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NOD2 antagonist 1 (compound 32) is a potent and selective NOD2 antagonist with an IC50 of 5.23 μM. NOD2 antagonist 1 inhibits Muramyl dipeptide (MDP)-induced IL-8 secretion in THP-1 cells and inhibits MDP-induced IL-6, IL-10, TNF-α release in PBMCs .
    NOD2 antagonist 1
  • HY-P990008
    Atrosab
    1 Publications Verification

    		 TNF Receptor Apoptosis Inflammation/Immunology
    Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
    Atrosab
  • HY-N6927R
    Isoforskolin (Standard)

    Coleonol B (Standard)

    		 Reference Standards TNF Receptor Interleukin Related Inflammation/Immunology
    Isoforskolin (Standard) is the analytical standard of Isoforskolin. This product is intended for research and analytical applications. Isoforskolin is the principle active component of C. forskohlii native to China. Isoforskolin reduces the secretion of lipopolysaccharide (LPS)-induced cytokines, namely TNF-α, IL-1β, IL-6 and IL-8, in human mononuclear leukocytes. Isoforskolin acts as an anti-inflammatory agent for the treatment of Lyme arthritis .
    Isoforskolin (Standard)
  • HY-W722277A
    LCC-12 formate

    		Interleukin Related NADH Dehydrogenase TNF Receptor JAK STAT IRAK Inflammation/Immunology
    LCC-12 (formate) is a copper (II) chelator and a derivative of the biguanide metformin (HY-B0627). LCC-12 (formate) reduces its hydrogen peroxide-dependent oxidation of NADH to NAD+. LCC-12 (formate) reduces IL-1β, IL-2, IL-6, IL-8, and TNF-α levels, as well as JAK2, STAT2, and IL-1 receptor-associated kinase 4 (IRAK4) levels in primary human cytokine-activated monocyte-derived macrophages (MDMs). LCC-12 (formate) reduces the number of CD80+ and CD86+ cytokine-activated MDMs. LCC-12 LCC-12 (formate) improves survival in a mouse model of sepsis induced by LPS or cecal ligation and puncture .
    LCC-12 formate
  • HY-124613
    Pyrazinib

    		Interleukin Related Metabolic Disease Inflammation/Immunology Cancer
    Pyrazinib is a inhibitor of angiogenesis and metabolism of oesophageal adenocarcinoma (oac) radioresistance, inhibiting the secretion of Il-6, Il-4, Il-8 and Il-13 cytokines from in oac radioresistant cells. Pyrazinib inhibits blood vessel development in zebrafish .
    Pyrazinib
  • HY-N0314R
    Pectolinarin (Standard)

    		Reference Standards Interleukin Related Prostaglandin Receptor Apoptosis Inflammation/Immunology
    Pectolinarin (Standard) is the analytical standard of Pectolinarin. This product is intended for research and analytical applications. Pectolinarin possesses anti-inflammatory activity . Pectolinarin inhibits secretion of IL-6 and IL-8, as well as the production of PGE2 and NO. Pectolinarin suppresses cell proliferation and inflammatory response and induces apoptosis via inactivation of the PI3K/Akt pathway .
    Pectolinarin (Standard)
  • HY-P3412
    MMI-0100

    		MAPKAPK2 (MK2) Inflammation/Immunology
    MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .
    MMI-0100
  • HY-128423AS
    Tylvalosin-d9

    Acetylisovaleryltylo​sin-d9

    		 Isotope-Labeled Compounds Apoptosis Antibiotic NF-κB Bacterial Others
    Tylvalosin-d9 (Acetylisovaleryltylo?sin-d9) is the deuterium labeled Tylvalosin (HY-128423A) . Tylvalosin is a third-generation macrolide, with anti-inflammatory property. Tylvalosin decreases the levels of IL-8, IL-6, IL-1β, PGE2, TNF-α and NO, and reduces the inflammatory cells recruitment and activation in mouse acute lung injury model .
    Tylvalosin-d9
  • HY-N2572R
    Nepetin (Standard)

    6-Methoxyluteolin (Standard)

    		 Reference Standards Interleukin Related Inflammation/Immunology
    Nepetin (Standard) is the analytical standard of Nepetin. This product is intended for research and analytical applications. Nepetin (6-Methoxyluteolin) is a natural flavonoid isolated from Eupatorium ballotaefolium HBK with potent anti-inflammatory activities. Nepetin inhibits IL-6, IL-8 and MCP-1 secretion with IC50 values of 4.43 μM, 3.42 μM and 4.17 μM, respectively in ARPE-19 cells .
    Nepetin (Standard)
  • HY-N7652
    Terminolic acid

    		Bacterial Interleukin Related Infection Inflammation/Immunology Cancer
    Terminolic acid is a pentacyclic triterpene glycoside and antibacterial agent. Terminolic acid can be isolated from Combretum racemosum. Terminolic acid inhibits proinflammatory cytokines by binding to the receptor active sites of IL-1β and IL-6. Terminolic acid reduces IL-8. Terminolic acid has antibacterial activity against Staphylococcus aureus, Escherichia coli and Enterococcus faecalis with MICs ranging from 64 to 256 μg/mL. Terminolic acid is used in colon cancer research .
    Terminolic acid
  • HY-P99165
    Teprotumumab
    1 Publications Verification

    		 IGF-1R TSH Receptor Endocrinology
    Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
    Teprotumumab
  • HY-173180
    5-LOX-IN-8

    		Lipoxygenase Interleukin Related TNF Receptor IFNAR Inflammation/Immunology
    5-LOX-IN-8 is a 5-LOX inhibitor with anti-inflammatory activity. 5-LOX-IN-8 suppresses IL-6, IL-1β, TNF-α and IFN-γ in macrophages and reduces IL-8 secretion in SW480 cells. 5-LOX-IN-8 reduces disease activity in a DSS colitis model. 5-LOX-IN-8 can be used for research of inflammatory bowel disease (IBD) .
    5-LOX-IN-8
  • HY-P10854
    TAT-N15

    		NF-κB Interleukin Related STAT Akt Neurological Disease Inflammation/Immunology
    TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke .
    TAT-N15
  • HY-B0506
    Nadifloxacin
    1 Publications Verification

    OPC7251

    		 Bacterial Antibiotic DNA/RNA Synthesis Interleukin Related Infection Inflammation/Immunology
    Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .
    Nadifloxacin
  • HY-P5836
    Citrullinated LL-37 1cit

    		Interleukin Related Bacterial Enterovirus Inflammation/Immunology
    Citrullinated LL-37 1cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 1cit does not alter the antiviral effect of LL-37 toward human rhinovirus. Citrullinated LL-37 1cit shows antibacterial activity toward S. aureus. Citrullinated LL-37 1cit causes a reduction in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B .
    Citrullinated LL-37 1cit
  • HY-120269
    CAY10512

    		NF-κB TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    CAY10512 is a NF-κB inhibitor. CAY10512 can suppress the upregulation of NF-κB-sensitive proinflammatory miRNAs (miRNA-9, miRNA-125b, miRNA-146a, miRNA-155) in cerebrospinal fluid and extracellular fluid. CAY10512 significantly reduces the release of pro-inflammatory cytokines (such as TNF-α, MCP-1, IL-8, IL-6). CAY10512 can be used for researchs on neuroinflammation, islet transplantation and microRNA regulation .
    CAY10512
  • HY-110133
    JTE-607
    3 Publications Verification

    		 Interleukin Related Inflammation/Immunology
    JTE-607, a highly selective inflammatory cytokine synthesis inhibitor, protects from endotoxin shock in mice. JTE-607 inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively . Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is the target of JTE-607 .
    JTE-607
  • HY-P991310
    Lpathomab

    LT3015; LT-3000

    		 LPL Receptor Neurological Disease Cancer
    Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Lpathomab
  • HY-110133A
    JTE-607 free base

    		Interleukin Related Inflammation/Immunology
    JTE-607 free base, a highly selective inflammatory cytokine synthesis inhibitor, protects from endotoxin shock in mice. JTE-607 free base inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively . Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is the target of JTE-607 free base .
    JTE-607 free base
  • HY-P5837
    Citrullinated LL-37 2cit

    		Interleukin Related Enterovirus Inflammation/Immunology
    Citrullinated LL-37 2cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 2cit reduces LL-37 activity against HRV at 10 μg/mL and reduces the antibacterial effect of LL-37. Citrullinated LL-37 2cit causes a reduction in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B. Citrullinated LL-37 2cit shows a moderate loss in the ability to reduce HRV-induced CCL5 secretion .
    Citrullinated LL-37 2cit
  • HY-P99555
    Tomaralimab

    OPN-305

    		 Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
    Tomaralimab
  • HY-W251428
    Phosphatidylglycerols (egg) sodium salt

    Egg PG

    		 Biochemical Assay Reagents Others
    Phosphatidylglycerols (PG) is a selective inhibitor targeting the TLR4 accessory protein CD14/MD-2 complex, inhibiting LPS or virus (such as RSV)-mediated inflammatory signaling pathways through competitive binding. Phosphatidylglycerols directly bind to viral particles to block infection, inhibit COX-2 expression to reduce the release of inflammatory factors (IL-6, IL-8), and improve oxidative stress by regulating mitochondrial membrane phospholipid remodeling. Phosphatidylglycerols can be taken orally or by inhalation and can be used in the study of chronic inflammatory diseases (such as atherosclerosis) and respiratory viral infections (such as RSV) .
    Phosphatidylglycerols (egg) sodium salt
  • HY-123789
    T5342126
    1 Publications Verification

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    T-5342126 is a toll-like receptor 4 (TLR4) antagonist. It reduces LPS-induced production of nitric oxide (NO) in RAW 264.7 cells (IC50=27.8 μM), as well as decreases LPS-induced IL-8, TNF-α, and IL-6 production in isolated human whole blood (IC50s=110.5, 315.6, and 318.4 μM, respectively). T-5342126 (82 mg/kg) reduces ethanol intake and the abundance of ionized calcium-binding adapter molecule 1 (Iba1), a marker of microglial activation, in the central nucleus of the amygdala in ethanol-dependent mice.
    T5342126
  • HY-B0506R
    Nadifloxacin (Standard)

    OPC7251 (Standard)

    		 Reference Standards Bacterial Antibiotic DNA/RNA Synthesis Interleukin Related Infection Inflammation/Immunology
    Nadifloxacin (Standard) is the analytical standard of Nadifloxacin (HY-B0506). This product is intended for research and analytical applications. Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .
    Nadifloxacin (Standard)
  • HY-159069
    Zymosan (ZM), 95%

    		Biochemical Assay Reagents Inflammation/Immunology
    Zymosan (ZM), 95% is a β-1,3-glucan polysaccharide that can be used as a functional food (as dietary fiber), phagocytic stimulus, and immune potentiator. Zymosan (ZM), 95% increases the levels of lysosomal enzyme secretion, upregulates the leukotriene production of monocytes, and enhances the release of proinflammatory cytokines, IL6 and TNFα, MCP-1, CXCL1, IL8, and MMP9 .
    Zymosan (ZM), 95%
  • HY-N0853
    Alisol A
    5 Publications Verification

    		 AMPK Acetyl-CoA Carboxylase PPAR MMP Interleukin Related Infection Cardiovascular Disease Metabolic Disease Cancer
    Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity .
    Alisol A
  • HY-B0506S1
    Nadifloxacin-d5

    OPC7251-d5

    		 Isotope-Labeled Compounds Antibiotic Bacterial DNA/RNA Synthesis Interleukin Related Infection Inflammation/Immunology
    Nadifloxacin-d5 (OPC7251-d5) is deuterium labeled Nadifloxacin (HY-B0506). Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .
    Nadifloxacin-d5
  • HY-P99390
    Tepoditamab

    MCLA 117

    		 CD3 Interleukin Related IFNAR TNF Receptor Inflammation/Immunology Cancer
    Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
    Tepoditamab
  • HY-178053
    AHR agonist 10

    		Aryl Hydrocarbon Receptor Cytochrome P450 Inflammation/Immunology
    AHR agonist 10 (B19) is a potent AHR agonist (EC50 = 2.01 nM). AHR agonist 10 can elevate the transcript levels of key AHR downstream pathway target genes, including CYP1A1 and CYP1B1. AHR agonist 10 can downregulate the expression levels of CD36, IL-18 and shows low cytotoxicity (>40 μM) to normal cells. AHR agonist 10 can suppress the expression of CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1, demonstrating that AHR agonist 10 effectively modulate inflammatory responses through AHR dependent signaling pathways. AHR agonist 10 can be used for psoriasis research .
    AHR agonist 10
  • HY-N0853R
    Alisol A (Standard)

    		Reference Standards AMPK Acetyl-CoA Carboxylase PPAR MMP Interleukin Related Infection Cardiovascular Disease Metabolic Disease Cancer
    Alisol A (Standard) is the analytical standard of Alisol A (HY-N0853). This product is intended for research and analytical applications. Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity .
    Alisol A (Standard)
  • HY-175655
    BChE/p38-α MAPK-IN-1

    		p38 MAPK Cholinesterase (ChE) Interleukin Related Neurological Disease Inflammation/Immunology
    BChE/p38-α MAPK-IN-1 is a selective dual inhibitor of hBChE (IC50 = 772 nM) and p38α MAPK (IC50 = 191 nM). BChE/p38-α MAPK-IN-1 reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) in cells. BChE/p38-α MAPK-IN-1 improves Scopolamine (HY-N0296)-induced cognitive impairment, as well as alleviates LPS (HY-D1056)-induced spatial learning impairment and exerts anti-neuroinflammatory effects in mice. BChE/p38-α MAPK-IN-1 can be used for the study of Alzheimer’s disease (AD) by targeting both cholinergic deficit and neuroinflammation .
    BChE/p38-α MAPK-IN-1
  • HY-12875
    BQU57

    		Ras Cancer
    BQU57 is a selective inhibitor of RalA/RalB small GTPases, with a binding potency (Kb) of 7.7 μM for RalB-GDP. BQU57 can block its interaction with effector proteins (such as SEC5 and EXO84), inhibiting tumor cell migration, invasion and non-adherent growth. BQU57 downregulates the NF-κB signaling pathway, reduces the expression of IL-6, IL-8 and MMP-13, and inhibits apoptosis by regulating the Bcl-2/Bax balance. BQU57 also protects the extracellular matrix by inhibiting the Ral/NF-κB pathway and can be used for the study of degenerative diseases. BQU57 exhibits significant antitumor activity in triple-negative breast cancer (TNBC) models, inhibiting orthotopic tumor growth and lung metastasis and enhancing paclitaxel chemotherapy sensitivity .
    BQU57
  • HY-N1353
    Rhamnocitrin
    2 Publications Verification

    		 p38 MAPK Cardiovascular Disease Inflammation/Immunology
    Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC50=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelial cells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .
    Rhamnocitrin
  • HY-N1353R
    Rhamnocitrin (Standard)

    		Reference Standards Others p38 MAPK Cardiovascular Disease Inflammation/Immunology
    Rhamnocitrin (Standard) is the analytical standard of Rhamnocitrin. This product is intended for research and analytical applications. Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC50=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelial cells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .
    Rhamnocitrin (Standard)
  • HY-N2736
    3′,4′,7-Trihydroxyflavone

    		Beta-lactamase COX Interleukin Related Bacterial JNK ERK p38 MAPK STAT Apoptosis NO Synthase Nuclear Factor of activated T Cells (NFAT) Lactate Dehydrogenase Reactive Oxygen Species (ROS) SOD Akt Caspase Bcl-2 Family Infection Neurological Disease Inflammation/Immunology
    3′,4′,7-Trihydroxyflavone is an orally active inhibitor of OXA-48 (IC50 = 1.89 μM) and COX-1 (IC50 = 36.37 μM). 3′,4′,7-Trihydroxyflavone exhibits antioxidant and anti-inflammatory properties, inhibiting the release of inflammatory cytokines such as IL-6, IL-8, and TNF-α. 3′,4′,7-Trihydroxyflavone inhibits H2O2-induced neuronal apoptosis and ROS accumulation, and exerts anti-neuroinflammatory effects by suppressing the JNK-STAT1 pathway. 3′,4′,7-Trihydroxyflavone exhibits antimicrobial and antibiotic-modifying activities against multidrug-resistant Gram-negative enteric bacteria. 3′,4′,7-Trihydroxyflavone inhibits RANKL-induced osteoclast formation via NFATc1. 3′,4′,7-Trihydroxyflavone activates the CREB-BDNF axis and restores scopolamine (HY-N0296)-induced memory deficits in mice .
    3′,4′,7-Trihydroxyflavone
  • HY-131688
    2-Chlorohexadecanoic acid

    		PARP Caspase Inflammation/Immunology
    2-Chlorohexadecanoic acid, an inflammatory lipid mediator, interferes with protein palmitoylation,induces ER-stress markers, reduced the ER ATP content, and activates transcription and secretion of IL-6 as well as IL-8.2-Chlorohexadecanoic acid disrupts the mitochondrial membrane potential and induces procaspase-3 and PARP cleavage.2-Chlorohexadecanoic acid can across blood-brain barrier (BBB) and compromises ER- and mitochondrial functions in the human brain endothelial cell line hCMEC/D3 .
    2-Chlorohexadecanoic acid
  • HY-17028A
    (Rac)-Besifloxacin hydrochloride

    		Bacterial Antibiotic DNA/RNA Synthesis Topoisomerase Infection Inflammation/Immunology
    (Rac)-Besifloxacin Hydrochloride is a fourth generation fluoroquinolone antibiotic. (Rac)-Besifloxacin Hydrochloride is a DNA gyrase and topoisomerase IV inhibitor. (Rac)-Besifloxacin Hydrochloride has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. (Rac)-Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research .
    (Rac)-Besifloxacin hydrochloride
  • HY-17028
    Besifloxacin Hydrochloride

    		Bacterial Antibiotic DNA/RNA Synthesis Topoisomerase Infection Inflammation/Immunology
    Besifloxacin Hydrochloride is a fourth generation fluoroquinolone antibiotic. Besifloxacin Hydrochloride is a DNA gyrase and topoisomerase IV inhibitor. Besifloxacin Hydrochloride has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research .
    Besifloxacin Hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: